Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SMMT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSummit announces Phase II and Phase III ivonescimab trial results in colorectal cancer
Filed June 1, 2026 · Period ending May 30, 2026 · ~1 min read
Key Changes
-
high
Summit disclosed new Phase II results from AK112-206, a global multicenter trial studying ivonescimab in first-line metastatic colorectal cancer, co-sponsored with partner Akeso.
Item 7.01 view on EDGAR → -
high
Partner Akeso published Phase III results from HARMONi-6, a China-based study of ivonescimab. This represents more advanced clinical evidence than Phase II data and was exclusively conducted by Akeso.
Item 7.01 view on EDGAR → -
medium
Summit scheduled a conference call for June 1, 2026 at 7:00am ET to discuss both trial datasets, with presentation slides attached to the filing.
Item 9.01 verify on EDGAR →
Summary
Summit Therapeutics announced clinical trial results for ivonescimab, its lead drug candidate, in colorectal cancer treatment. The company disclosed new Phase II data from its global AK112-206 trial in first-line metastatic colorectal cancer, co-sponsored with Chinese partner Akeso. Additionally, Akeso published Phase III results from HARMONi-6, a China-only study that Akeso exclusively controlled and analyzed.
Retail investors should care because these announcements represent key clinical milestones for Summit's pipeline. Phase III data typically carries more weight than Phase II, and positive results could accelerate regulatory pathways and partnership opportunities. The dual announcement suggests coordinated disclosure of meaningful clinical progress across multiple geographies.
Watch the June 1 conference call and review the actual trial data in the press releases. Key metrics to monitor include response rates, safety profiles, and how results compare to existing colorectal cancer treatments. Also note the division of control between Summit and Akeso, as the China trial was exclusively managed by the partner.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Summit Therapeutics filed three exhibits: two press releases (May 30 and May 31, 2026) and presentation slides for a June 1, 2026 conference call.
Added in current filing · view on EDGAR →
99.1 Press Release, dated May 30, 2026
99.2 Press Release, dated May 31, 2026
99.3 Presentation Slides for June 1, 2026 Conference Call
The company disclosed three exhibits: two press releases dated May 30 and May 31, 2026, and presentation slides for a June 1, 2026 conference call. Without access to the actual exhibit content, the materiality and substance of these disclosures cannot be determined from this 8-K filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify